Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: Jan. 2, 2025
The
first
step
to
reducing
the
growing
burden
of
cardiovascular
disease
(CVD)
is
find
modifiable
risk
factors
with
highest
in
each
population.
Urban
and
rural
citizens
may
have
different
priorities
this
regard.
This
study
aimed
compare
10-year
incidence
probability
CVD
events
its
associated
between
urban
areas
Iran.
Data
was
extracted
from
two
big
cohorts,
Fasa
Adults
Cohort
Study
(FACS)
Shiraz
Heart
(SHS),
participation
over
12,000
general
Linear
regression
models
were
used
test
difference
populations.
Totally,
6,258
FACS
6,101
SHS
participants
entered
study.
had
a
significantly
higher
mean
ASCVD
score
(4.43%
vs.
5.51%,
p-value
<
0.001).
Also,
they
showed
body
mass
index,
waist
circumference,
cholesterol
level,
fasting
blood
glucose
systolic
pressure,
educational
attainment,
occupational
status.
However,
prevalence
smoking
areas.
Notably,
socioeconomic
parameters
including
marital,
occupational,
statuses
seem
strong
impact
on
factors.
After
adjustment
for
all
confounders,
living
seemed
be
atherosclerotic
(β
=
0.78,
95%CI:
[0.69–1.05]),
which
consistent
across
both
sexes.
Given
profiles
these
regions,
preventive
strategies
should
precisely
separately
designed
population
by
health
authorities
policymakers
order
reduce
toll
efficiently.
Circulation,
Journal Year:
2023,
Volume and Issue:
148(24), P. 1982 - 2004
Published: Nov. 10, 2023
Cardiovascular-kidney-metabolic
(CKM)
syndrome
is
a
novel
construct
recently
defined
by
the
American
Heart
Association
in
response
to
high
prevalence
of
metabolic
and
kidney
disease.
Epidemiological
data
demonstrate
higher
absolute
risk
both
atherosclerotic
cardiovascular
disease
(CVD)
heart
failure
as
an
individual
progresses
from
CKM
stage
0
3,
but
optimal
strategies
for
assessment
need
be
refined.
Absolute
with
goal
match
type
intensity
interventions
predicted
expected
treatment
benefit
remains
cornerstone
primary
prevention.
Given
growing
number
therapies
our
armamentarium
that
simultaneously
address
all
3
axes,
prediction
equations
are
needed
incorporate
predictors
outcomes
relevant
context.
This
should
also
include
social
determinants
health,
which
key
upstream
drivers
CVD,
more
equitably
estimate
risk.
scientific
statement
summarizes
background,
rationale,
clinical
implications
newly
developed
sex-specific,
race-free
equations:
PREVENT
(AHA
Predicting
Risk
CVD
Events).
The
enable
10-
30-year
estimates
total
(composite
failure),
estimated
glomerular
filtration
rate
predictor,
adjust
competing
non-CVD
death
among
adults
30
79
years
age.
Additional
models
accommodate
enhanced
predictive
utility
addition
factors
when
clinically
indicated
measurement
(urine
albumin-to-creatinine
ratio
hemoglobin
A1c)
or
health
(social
deprivation
index)
available.
Approaches
implement
risk-based
prevention
using
across
various
settings
discussed.
Circulation,
Journal Year:
2024,
Volume and Issue:
149(24)
Published: May 14, 2024
The
"2024
ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS
Guideline
for
the
Management
of
Lower
Extremity
Peripheral
Artery
Disease"
provides
recommendations
to
guide
clinicians
in
treatment
patients
with
lower
extremity
peripheral
artery
disease
across
its
multiple
clinical
presentation
subsets
(ie,
asymptomatic,
chronic
symptomatic,
limb-threatening
ischemia,
and
acute
limb
ischemia).
New England Journal of Medicine,
Journal Year:
2023,
Volume and Issue:
389(25), P. 2319 - 2330
Published: Nov. 11, 2023
Percutaneous
coronary
intervention
(PCI)
is
frequently
performed
to
reduce
the
symptoms
of
stable
angina.
Whether
PCI
relieves
angina
more
than
a
placebo
procedure
in
patients
who
are
not
receiving
antianginal
medication
remains
unknown.
We
conducted
double-blind,
randomized,
placebo-controlled
trial
with
Patients
stopped
all
medications
and
underwent
2-week
symptom
assessment
phase
before
randomization.
were
then
randomly
assigned
1:1
ratio
undergo
or
followed
for
12
weeks.
The
primary
end
point
was
score,
which
calculated
daily
on
basis
number
episodes
that
occurred
given
day,
prescribed
clinical
events,
including
occurrence
unblinding
owing
unacceptable
acute
syndrome
death.
Scores
range
from
0
79,
higher
scores
indicating
worse
health
status
respect
A
total
301
randomization:
151
group
150
group.
mean
(±SD)
age
64±9
years,
79%
men.
Ischemia
present
one
cardiac
territory
242
(80%),
two
territories
52
(17%),
three
7
(2%).
In
target
vessels,
median
fractional
flow
reserve
0.63
(interquartile
range,
0.49
0.75),
instantaneous
wave-free
0.78
0.55
0.87).
At
12-week
follow-up,
score
2.9
5.6
(odds
ratio,
2.21;
95%
confidence
interval,
1.41
3.47;
P<0.001).
One
patient
had
leading
unblinding.
Acute
syndromes
4
6
Among
little
no
objective
evidence
ischemia,
resulted
lower
procedure,
better
(Funded
by
National
Institute
Health
Care
Research
Imperial
Biomedical
Centre
others;
ORBITA-2
ClinicalTrials.gov
number,
NCT03742050.)
Circulation,
Journal Year:
2024,
Volume and Issue:
150(4)
Published: June 4, 2024
BACKGROUND:
Cardiovascular
disease
and
stroke
are
common
costly,
their
prevalence
is
rising.
Forecasts
on
the
of
risk
factors
clinical
events
crucial.
METHODS:
Using
2015
to
March
2020
National
Health
Nutrition
Examination
Survey
2019
Medical
Expenditure
Panel
Survey,
we
estimated
trends
in
for
cardiovascular
based
adverse
levels
Life’s
Essential
8
stroke.
We
projected
through
2050,
overall
by
age
race
ethnicity,
accounting
changes
demographics.
RESULTS:
estimate
that
among
adults,
hypertension
will
increase
from
51.2%
61.0%
2050.
Diabetes
(16.3%
26.8%)
obesity
(43.1%
60.6%)
increase,
whereas
hypercholesterolemia
decline
(45.8%
24.0%).
The
prevalences
poor
diet,
inadequate
physical
activity,
smoking
improve
over
time,
sleep
worsen.
Prevalences
coronary
(7.8%
9.2%),
heart
failure
(2.7%
3.8%),
(3.9%
6.4%),
atrial
fibrillation
(1.7%
2.4%),
total
(11.3%
15.0%)
rise.
Clinical
CVD
affect
45
million
including
more
than
184
adults
2050
(>61%).
Similar
children.
Most
be
worse
people
identifying
as
American
Indian/Alaska
Native
or
multiracial,
Black,
Hispanic.
CONCLUSIONS:
many
most
established
diseases
next
30
years.
public
health
interventions
needed
effectively
manage,
stem,
even
reverse
these
trends.
Circulation,
Journal Year:
2024,
Volume and Issue:
150(4)
Published: June 4, 2024
BACKGROUND:
Quantifying
the
economic
burden
of
cardiovascular
disease
and
stroke
over
coming
decades
may
inform
policy,
health
system,
community-level
interventions
for
prevention
treatment.
METHODS:
We
used
nationally
representative
health,
economic,
demographic
data
to
project
care
costs
attributable
key
risk
factors
(hypertension,
diabetes,
hypercholesterolemia)
conditions
(coronary
heart
disease,
stroke,
failure,
atrial
fibrillation)
through
2050.
The
human
capital
approach
was
estimate
productivity
losses
from
morbidity
premature
mortality
due
conditions.
RESULTS:
One
in
3
US
adults
received
a
factor
or
condition
2020.
Annual
inflation-adjusted
(2022
dollars)
are
projected
triple
between
2020
2050,
$400
billion
$1344
billion.
For
conditions,
annual
almost
quadruple,
$393
$1490
billion,
increase
by
54%,
$234
$361
Stroke
is
account
largest
absolute
costs.
Large
relative
increases
among
Asian
American
population
(497%)
Hispanic
(489%)
reflect
size
these
populations.
CONCLUSIONS:
overt
United
States
substantially
decades.
Development
deployment
cost-effective
programs
policies
promote
urgently
needed
rein
equitably
enhance
health.
New England Journal of Medicine,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 30, 2024
The
appropriate
duration
of
treatment
with
beta-blocker
drugs
after
a
myocardial
infarction
is
unknown.
Data
are
needed
on
the
safety
and
efficacy
interruption
long-term
to
reduce
side
effects
improve
quality
life
in
patients
history
uncomplicated
infarction.
Global Heart,
Journal Year:
2024,
Volume and Issue:
19(1)
Published: Jan. 1, 2024
Background:
Secondary
prevention
lifestyle
and
pharmacological
treatment
of
atherosclerotic
cardiovascular
disease
(ASCVD)
reduce
a
high
proportion
recurrent
events
mortality.
However,
significant
gaps
exist
between
guideline
recommendations
usual
clinical
practice.
Objectives:
Describe
the
state
art,
roadblocks,
successful
strategies
to
overcome
them
in
ASCVD
secondary
management.
Methods:
A
writing
group
reviewed
guidelines
research
papers
received
inputs
from
an
international
committee
composed
health
systems
experts
about
article's
structure,
content,
draft.
Finally,
external
expert
paper.
Results:
Smoking
cessation,
physical
activity,
diet
weight
management,
antiplatelets,
statins,
beta-blockers,
renin-angiotensin-aldosterone
system
inhibitors,
cardiac
rehabilitation
Potential
roadblocks
may
occur
at
individual,
healthcare
provider,
levels
include
lack
access
medicines,
inertia,
primary
care
infrastructure
or
built
environments
that
support
preventive
behaviours.
Possible
solutions
improving
literacy,
self-management
strategies,
national
policies
improve
medication
(including
fix-dose
combination
therapy),
implementing
programs,
incorporating
digital
interventions.
Digital
tools
are
being
examined
range
settings
enhancing
self-management,
risk
factor
control,
rehab.
Conclusions:
Effective
for
management
exist,
but
there
barriers
their
implementation.
WHF
roadmaps
can
facilitate
development
strategic
plan
identify
implement
local
level
approaches
prevention.
Diabetes Care,
Journal Year:
2024,
Volume and Issue:
48(Supplement_1), P. S207 - S238
Published: Dec. 9, 2024
The
American
Diabetes
Association
(ADA)
"Standards
of
Care
in
Diabetes"
includes
the
ADA's
current
clinical
practice
recommendations
and
is
intended
to
provide
components
diabetes
care,
general
treatment
goals
guidelines,
tools
evaluate
quality
care.
Members
ADA
Professional
Practice
Committee,
an
interprofessional
expert
committee,
are
responsible
for
updating
Standards
annually,
or
more
frequently
as
warranted.
For
a
detailed
description
standards,
statements,
reports,
well
evidence-grading
system
full
list
Committee
members,
please
refer
Introduction
Methodology.
Readers
who
wish
comment
on
invited
do
so
at
professional.diabetes.org/SOC.
Circulation,
Journal Year:
2024,
Volume and Issue:
150(6)
Published: June 20, 2024
There
is
significant
variability
in
the
efficacy
and
safety
of
oral
P2Y12
inhibitors,
which
are
used
to
prevent
ischemic
outcomes
common
diseases
such
as
coronary
peripheral
arterial
disease
stroke.
Clopidogrel,
a
prodrug,
most
inhibitor
activated
primarily
after
being
metabolized
by
highly
polymorphic
hepatic
cytochrome
CYP2C219
enzyme.
Loss-of-function
genetic
variants
